Search

Your search keyword '"Bazzoli F."' showing total 991 results
Start Over Author "Bazzoli F."
991 results on '"Bazzoli F."'

204. 53 P Diagnosis of atrophic gastritis in the general population based upon a combination of three non invasive tests

Author

Zagari, M.R., primary, Fiocca, R., additional, Casanova, S., additional, Pozzato, P., additional, Lunedei, V., additional, De Luca, L., additional, Ricciardiello, L., additional, Martuzzi, C., additional, Fuccio, L., additional, Maltoni, S., additional, Sipponen, P., additional, Roda, E., additional, and Bazzoli, F., additional

Published
2002
Full Text
View/download PDF

205. 54 P Helicobacter pylori (HP) infection and risk of intestinal metaplasia in first-degree relatives of gastric cancer patients: A population based study

Author

Zagari, M.R., primary, Casanova, S., additional, Fiocca, R., additional, Pozzato, P., additional, Martuzzi, C., additional, Ricciardiello, L., additional, De Luca, L., additional, Maltoni, S., additional, Fuccio, L., additional, Lunedei, V., additional, Di Marco, M., additional, D'Errico, A., additional, Grigioni, W., additional, Panuccio, D., additional, Cioffi, G., additional, Roda, E., additional, and Bazzoli, F., additional

Published
2002
Full Text
View/download PDF

208. 9 P Prevalence of asymptomatic endoscopic lesions of the upper gastrointestinal tract: Preliminary results of the Loiano-Monghidoro population study

Author

Zagari, R.M., primary, Pozzato, P., additional, Martuzzi, C., additional, Ricciardiello, L., additional, Lunedei, V., additional, Di Marco, M., additional, De Luca, L., additional, Maltoni, S., additional, Fuccio, L., additional, Casanova, S., additional, Fiocca, R., additional, D'Errico, A., additional, Cioffi, G., additional, Panuccio, D., additional, Grigioni, W., additional, Roda, E., additional, and Bazzoli, F., additional

Published
2002
Full Text
View/download PDF

209. 36 OP Loss of HMLH1 due to promoter hypermethylation causes high frequency of microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer

Author

Ricciardiello, L., primary, Goel, A., additional, Mantovani, V., additional, Fiorini, T., additional, Fossi, S., additional, Chang, D.K., additional, Lunedei, V., additional, Zagari, R.M., additional, Martinelli, G.N., additional, Boland, C.R., additional, Roda, E., additional, and Bazzoli, F., additional

Published
2002
Full Text
View/download PDF

210. Diagnosis of atrophic gastritis based upon a combination of three non invasive tests: Preliminary results of the Loiano-Monghidoro project

Author

Nicolini, G., primary, Zagari, R.M., additional, Pozzato, P., additional, Lunedei, V., additional, De Luca, L., additional, Antonini, F., additional, Ricciardiello, L., additional, Fossi, S., additional, Berretti, D., additional, Martuzzi, C., additional, Fuccio, L., additional, Maltoni, S., additional, Sipponen, P., additional, Bazzoli, F., additional, and Roda, E., additional

Published
2001
Full Text
View/download PDF

212. Helicobacter pylori infection and Intestinal Metaplasia in first-degree relatives of gastric cancer patients: the Loiano-Monghidoro projects

Author

Zagari, R.M., primary, Casanova, S., additional, Fiocca, R., additional, Nicolini, G., additional, Pozzato, P., additional, Fossi, S., additional, Lunedei, V., additional, Antonini, F., additional, De Luca, L., additional, Fuccio, L., additional, Martuzzi, C., additional, Maltoni, S., additional, Berretti, D., additional, D'Errico, A., additional, Grigioni, W., additional, Bazzoli, F., additional, and Roda, E., additional

Published
2001
Full Text
View/download PDF

214. Endoscopic findings on loiano-monghidoro population: Preliminary results of the loiano-monghidoro population based study

Author

Bazzoli, F., primary, Palli, D., additional, Zagari, R.M., additional, Masala, G., additional, Nicolini, G., additional, Fossi, S., additional, Pozzato, P., additional, Panuccio, D., additional, Ceroti, M., additional, De Luca, L., additional, Berretti, D., additional, Martuzzi, C., additional, Maltoni, S., additional, Fuccio, L., additional, Ricciardiello, L., additional, and Roda, E., additional

Published
2000
Full Text
View/download PDF

215. Duodenal ulcer, body mass and smoking are strong predictors of δ13 CO2 in a large series of Helicobacter pylori positive subjects (Loiano-monghidoro study)

Author

Bazzoli, F., primary, Palli, D., additional, Zagari, R.M., additional, Masala, G., additional, Pozzato, P., additional, Nicolini, G., additional, Fossi, S., additional, De Luca, L., additional, Ceroti, M., additional, Berretti, D., additional, Ricciardiello, L., additional, Martuzzi, C., additional, Maltoni, S., additional, Fuccio, L., additional, Panuccio, D., additional, Festi, D., additional, and Roda, E., additional

Published
2000
Full Text
View/download PDF

217. Efficacy of omeprazole plus amoxicillin or amoxicillin plus clarithromicin for 1 week or 2 weeks in the Helicobacter pylori eradication in patients with duodenal ulcer

Author

Bazzoli, F., primary, Bianchi Porro, G., additional, Fiocca, R., additional, Gasbarrini, G., additional, Roda, E., additional, Fossi, S., additional, Pozzato, P., additional, Nicolini, N., additional, De Luca, L., additional, Berretti, D., additional, Martuzzi, C., additional, Maltoni, S., additional, Fuccio, L., additional, and Zagari, M., additional

Published
2000
Full Text
View/download PDF

218. Agreement of helicobacter pylori infection and δ13 CO2 excretion in a large series of spouse pairs (Loianomonghidoro study)

Author

Palli, D., primary, Nicolini, G., additional, Masala, G., additional, Fossi, S., additional, Pozzato, P., additional, De Luca, L., additional, Zagari, R.M., additional, Ceroti, M., additional, Pannuccio, D., additional, Berretti, D., additional, Ricciardiello, L., additional, Martuzzi, C., additional, Maltoni, S., additional, Fuccio, L., additional, Festi, D., additional, Roda, E., additional, and Bazzoli, F., additional

Published
2000
Full Text
View/download PDF

219. Natural history of Helicobacter pylori infection: Preliminary results of loiano-monghidoro population based study

Author

Bazzoli, F., primary, Palli, D., additional, Zagari, R.M., additional, Masala, G., additional, Nicolini, G., additional, Fossi, S., additional, Pozzato, P., additional, Panuccio, D., additional, Ceroti, M., additional, De Luca, L., additional, Berretti, D., additional, Martuzzi, C., additional, Maltoni, S., additional, Fuccio, L., additional, Ricciardiello, L., additional, and Roda, E., additional

Published
2000
Full Text
View/download PDF

224. Helicobacter pylori: Optimum Diagnosis and Test of Cure

Author

Bazzoli, F., primary, Zagari, R.M., additional, Pozzato, P., additional, Fossi, S., additional, Ricciardiello, L., additional, De Luca, L., additional, Nicolini, G., additional, Berretti, D., additional, Maltoni, S., additional, Gorini, B., additional, Martuzzi, C., additional, Fuccio, L., additional, and Roda, E., additional

Published
1999
Full Text
View/download PDF

225. Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well)

Author

Festi, D, primary, Colecchia, A, additional, Orsini, M, additional, Sangermano, A, additional, Sottili, S, additional, Simoni, P, additional, Mazzella, G, additional, Villanova, N, additional, Bazzoli, F, additional, Lapenna, D, additional, Petroni, ML, additional, Pavesi, S, additional, Neri, M, additional, and Roda, E, additional

Published
1998
Full Text
View/download PDF

226. A comparative trial to optimize the protocol of the 13C urea breath test for the diagnosis of Helicobacter pylori infection

Author

Zagari, R.M., primary, Pozzato, P., additional, Bazzoli, F., additional, Fossi, S., additional, Ricciardiello, L., additional, Nicolini, G., additional, Berretti, D., additional, de Luca, L., additional, Alampi, G., additional, Salfi, N., additional, Martinelli, G., additional, Sottili, S., additional, Festi, D., additional, Neri, M., additional, Simoni, P., additional, Roda, A., additional, and Roda, E., additional

Published
1998
Full Text
View/download PDF

229. A population based study of Helicobacter pylori infection. V: Excess δ13CO2 excretion as an indicator of bacterial load is associated with demographic and individual factors

Author

Bazzoli, F., primary, Zagari, R.M., additional, Palli, D., additional, Festi, D., additional, Pozzato, P., additional, Masala, G., additional, Sottili, S., additional, Panuccio, D., additional, Ricciardiello, L., additional, Nicolini, G., additional, Fossi, S., additional, Edili, E., additional, Simoni, P., additional, Roda, A., additional, and Roda, E., additional

Published
1998
Full Text
View/download PDF

232. Eradication

Author

Graham, D. Y., primary, Realdi, G., additional, Bazzoli, F., additional, Dore, M. P., additional, Ferrini, G., additional, Glupczynski, Y., additional, Kusstatscher, S., additional, Mura, I., additional, Naim, G., additional, Pilotto, A., additional, Sanna, G., additional, Scaglione, F., additional, and Savarino, V., additional

Published
1997
Full Text
View/download PDF

243. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer.

Author

Fuccio, L., Guido, A., Laterza, L., Eusebi, L. H., Busutti, L., Bunkheila, F., Barbieri, E., and Bazzoli, F.

Subjects
BECLOMETHASONE dipropionate, PROSTATE cancer patients, RECTAL medication, RADIOTHERAPY, PLACEBOS
Abstract

Aliment Pharmacol Ther 2011; 34: 628-637 Summary Background Radiotherapy is an established treatment modality for prostate cancer; however, up to a third of patients develops a radiation-induced proctopathy. Aim To assess the effect of topical beclomethasone dipropionate (BDP) in the prevention of radiation-induced proctopathy in patients undergoing radiotherapy for prostate cancer through a double-blind, placebo-controlled, randomised trial. Methods Patients were randomised either to BDP or to placebo (PL). Patients received daily a 3 mg BDP enema or identical-looking PL during radiotherapy and, subsequently, two 3 mg BDP suppositories or PL for 4 more weeks. Clinical and endoscopic evaluations before, 3 and 12 months after the end of radiotherapy were assessed with the RTOG/EORTC toxicity scales, the modified Simple Clinical Colitis Activity Index (SCCAI), the modified Inflammatory Bowel disease Quality of Life Index (IBDQ) and the Vienna Rectoscopy Score (VRS). Results From June 2007 to October 2008, 120 patients were randomised to the BDP ( n = 60) and PL ( n = 60) arms and were followed up for 12 months. The overall assessment of rectal side effects did not show significant differences between the two groups of treatment. However, when only rectal bleeding was considered, a significantly reduced risk was observed in patients on BDP (OR 0.38; 95% CI 0.17-0.86; P = 0.02; NNT = 5). Patients on BDP had also significantly lower VRS scores ( P = 0.028) and significantly higher IBDQ scores ( P = 0.034). Conclusions Preventive treatment with topical rectal BDP during radiotherapy for prostate cancer significantly reduces the risk of rectal bleeding and radiation-induced mucosal changes and improves patient's quality of life, but does not influence other radiation-induced symptoms. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

246. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano--Monghidoro study.

Author

Zagari, R. M., Fuccio, L., Wallander, M.-A., Johansson, S., Fiocca, R., Casanova, S., Farahmand, B. Y., Winchester, C. C., Roda, E., and Bazzoli, F.

Subjects
GASTROESOPHAGEAL reflux, SYMPTOMS, DISEASE complications, BARRETT'S esophagus, ESOPHAGUS diseases, HIATAL hernia, ENDOSCOPY
Abstract

Objective: Existing endoscopy-based data on gastro-oesophageal reflux disease (GOAD) in the general population are scarce. This study aimed to evaluate typical symptoms and complications of GOAD, and their associated risk factors, in a representative sample of the Italian population. Methods: 1533 adults from two Italian villages were approached to undergo symptom assessment using a validated questionnaire and upper gastrointestinal endoscopy. Data were obtained from 1033 individuals (67.4% response rate). Results: The prevalence of reflux symptoms was 44.3%; 23.7% of the population experienced such symptoms on at least 2 days per week (frequent symptoms). The prevalence rates of oesophagitis and Barrett's oesophagus in the population were 11.8% and 1.3%, respectively. Both frequent (relative risk (AR) 2.6; 95% confidence interval (Cl) 1.7 to 3.9) and infrequent (AR 1.9; 95% Cl 1.2 to 3.0) reflux symptoms were associated with the presence of oesophagitis. No reflux symptoms were reported by 32.8% of individuals with oesophagitis and 46.2% of those with Barrett's oesophagus. Hiatus hernia was associated with frequent reflux symptoms and oesophagitis, and was present in 76.9% of those with Barrett's oesophagus. We found no association between body mass index and ref lux symptoms or oesophagitis. Conclusions: GOAD is common in Italy, but the prevalence of Barrett's oesophagus in the community is lower than has been reported in selected populations. Both frequent and infrequent reflux symptoms are associated with an increased risk of oesophagitis. Individuals with oesophagitis and Barrett's oesophagus often have no reflux symptoms. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

247. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.

Author

Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F, Fuccio, Lorenzo, Minardi, Maria Eugenia, Zagari, Rocco Maurizio, Grilli, Diego, Magrini, Nicola, and Bazzoli, Franco

Abstract

Background: Proton-pump inhibitor (PPI)-based triple therapy is the recommended first-line treatment for Helicobacter pylori infection. A consensus on treatment duration is lacking.Purpose: To summarize the benefits and harms of different durations of PPI-based triple therapy.Data Sources: PubMed, EMBASE, the Cochrane Library, and proceedings of major meetings through May 2007.Study Selection: English-language reports of randomized, controlled trials that compared duration (7, 10, or 14 days) of triple therapy and in which adequate testing confirmed the initial H. pylori infection and its eradication.Data Extraction: Two authors independently extracted data on study design, treatment, number of patients enrolled and number of patients with successful eradication, disease at enrollment, testing, adverse effects, year of publication, publication format, and country.Data Synthesis: Of 21 included studies, 11 compared 7-day therapy with 10-day therapy, and 13 compared 7-day therapy with 14-day therapy. Meta-analysis yielded relative risks (RRs) for eradication of 1.05 (95% CI, 1.01 to 1.10) for 7-day compared with 10-day amoxicillin-containing triple therapy (10 studies) and 1.07 (CI, 1.02 to 1.12) for 7-day compared with 14-day therapy (11 studies). Meta-analysis of the 3 studies that compared 7-day with 14-day metronidazole-containing therapy yielded an RR of 1.08 (CI, 0.96 to 1.22). The 7-day versus 10-day comparisons yielded RRs of 1.03 (CI, 0.97 to 1.10) for peptic ulcer disease and 1.10 (CI, 1.02 to 1.20) for nonulcer dyspepsia. For the 7-day versus 14-day comparisons, the RRs were 1.04 (CI, 0.99 to 1.09) and 1.03 (CI, 0.88 to 1.20), respectively. The RRs for frequency of adverse events were 0.98 (CI, 0.85 to 1.14) and 1.08 (CI, 0.84 to 1.40) for 7-day therapy compared with 10- and 14-day therapy, respectively. Diarrhea and taste disturbance were the most frequently reported adverse events (5%).Limitations: Subgroup analyses were limited by the few studies evaluating different drug regimens and disease at enrollment. Seventeen of the included studies had poor methodological quality or inadequate reporting.Conclusion: Available data suggest that extending triple therapy beyond 7 days is unlikely to be a clinically useful strategy. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

248. Current concepts in the management of Helicobacter pylon infection: the Maastricht III Consensus Report.

Author

Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, I., Vakil, N., and Kuipers, E. J.

Subjects
HELICOBACTER pylori, HELICOBACTER diseases, STOMACH cancer, PEPTIC ulcer, GASTRITIS, THROMBOPENIC purpura, GASTRIC mucosa, ABDOMINAL pain
Abstract

Background: Guidelines on the management of Helicobacterpylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylon eradication for the prevention of gastric cancer. Results: Eradication of H pylon infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (c) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a ‘test and treat’ strategy if other causes are excluded. Eradication of H pylon infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylon eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylon infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylon infection has the potential to reduce the risk of gastric cancer development. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

249. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.

Author

FUCCIO, L., ZAGARI, R. M., MINARDI, M. E., and BAZZOLI, F.

Subjects
CANCER chemoprevention, TREATMENT of helicobacter pylori infections, CLINICAL epidemiology, MEDICAL screening, GASTRIC diseases, PRECANCEROUS conditions
Abstract

Background Helicobacter pylori is recognized as one of the most significant risk factors for gastric cancer, and H. pylori eradication has been proposed as a possible primary chemo-preventive strategy to reduce gastric cancer incidence. Aim To evaluate the available evidence on the efficacy of H. pylori eradication in the prevention of gastric cancer. Methods Epidemiological, observational and interventional studies, as well as decisional models, were taken into account in this review. Results Large-scale epidemiological studies clearly link H. pylori infection with non-cardia gastric cancer. Current evidence suggests that, in a subpopulation of treated subjects, H. pylori eradication prevents the progression of preneoplastic lesions. Studies that have attempted to evaluate the effect of H. pylori eradication on the incidence of gastric cancer have not provided definitive answers. H. pylori eradication seems to reduce the incidence of gastric cancer in patients without baseline precancerous gastric lesions. Decisional models suggest that H. pylori screening could be cost-effective, but there is not yet sufficient evidence to support the setting up of a general screening programme. Conclusion Helicobacter pylori eradication is a plausible intervention for gastric cancer prevention; however, it seems to be relevant in only a subset of subjects. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results